- Home
- NOMA vs HURA Comparison
NOMA vs HURA Comparison
Compare NOMA & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NOMA | HURA |
|---|---|---|
| Founded | 2023 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 115.0M | 131.8M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | NOMA | HURA |
|---|---|---|
| Price | $4.51 | $0.68 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 309.9K | ★ 328.4K |
| Earning Date | 01-01-0001 | 02-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $885,694.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.35 | $0.68 |
| 52 Week High | $57.70 | $5.27 |
Technical Indicators
Market Signals| Indicator | NOMA | HURA |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 29.13 |
| Support Level | N/A | $0.68 |
| Resistance Level | N/A | $0.78 |
| Average True Range (ATR) | 0.00 | 0.06 |
| MACD | 0.00 | 0.04 |
| Stochastic Oscillator | 0.00 | 20.20 |
Price Performance
Historical ComparisonAbout NOMA NOMADAR Corp.
Nomadar Corp operates at the intersection of sports and technology, focusing on high-performance training programs and cultural exchange. The company aims to connect athletes, coaches, and fans through innovative technological solutions, enhancing sports development beyond physical borders. It offers services like the High Performance Training (HPT) program and promotes the legacy of iconic athletes.
About HURA TuHURA Biosciences Inc.
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.